Quisel John D sold $2.4M of IRON
Quisel John D (Chief Executive Officer) sold 34,000 shares of Disc Medicine, Inc. (IRON) at an average of $70.21 ($69.92–$71.61, $2.39M total) across 3 trades on 2026-06-18 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s disclosed open-market sale of 34,000 shares (~$2.39M) at a weighted average ~$70.21/share, with a stated 10b5-1 pre-arranged plan.
Market read
Traders may monitor for follow-on insider activity, but this filing alone does not change the company’s fundamentals.
What to watch
The filing does not disclose reasons for sale, and the trades occurred on 2026-06-18—any market reaction on 6/23 would be about disclosure timing, not new fundamentals.
Background
The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).
Ticker impact
SEC Form 4 shows CEO John D Quisel sold 34,000 shares of IRON for ~$2.39M at ~$70.21/share under a 10b5-1 plan.
Likely limited near-term price impact; any effect is more sentiment/positioning than new company fundamentals.
The filing is primary-source and time-stamped, but the transaction is explicitly under a 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
No direct sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may be routine liquidity management rather than a bearish signal.
Key entities
- public_companyIRON
Disc Medicine, Inc.; subject of the Form 4 insider sale disclosure.
- insiderQuisel John D
CEO and officer/director who sold shares.
- trading_mechanism10b5-1 plan
Pre-arranged plan noted as Yes, which typically reduces interpretive signal.